RxDoctor Payments Data

Jonathan Block, MD

Urology · New Hartford, NYNPI 1770679763

Payments from drug & device makers

$13,236in general payments, 2019–2025

Across 596 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$2K
  • Johnson & Johnson$1K
  • Bayer$814
  • AbbVie$757
  • Dendreon Pharmaceuticals LLC$602
  • Urogen Pharma, Inc.$501
  • plus $8K from 46 others

What the payments were for

  • Speaking & faculty fees$4003%
  • Food & beverage$11,55887%
  • Education$1,27810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,236 in reported general payments places this provider in the 80th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$484,221
Medicare patients
1,131
Services billed
21,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron86$73,409
MyrbetriqMirabegron56$66,011
Methenamine Hippurate152$20,228
Tamsulosin Hcl887$17,328
Mirabegron ErMirabegron19$12,422
Alfuzosin Hcl ErAlfuzosin Hcl440$12,028
Potassium Citrate ErPotassium Citrate71$10,392
Finasteride715$9,440
Tolterodine Tartrate ErTolterodine Tartrate52$6,863
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl25$5,306
Dutasteride173$4,836
Solifenacin Succinate46$3,864
Fesoterodine Fumarate ErFesoterodine Fumarate28$2,554
Allopurinol158$2,512
Tadalafil12$2,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$251$73,40986 claims
Astellas Pharma US IncMyrbetriq$1,777$66,01156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 urology providers in New York.

Other urology in New Hartford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →